Patents by Inventor David B. Whitman
David B. Whitman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240166661Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.Type: ApplicationFiled: December 1, 2023Publication date: May 23, 2024Inventors: Robert L. Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
-
Patent number: 11878982Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.Type: GrantFiled: May 25, 2021Date of Patent: January 23, 2024Assignee: 89BIO LTDInventors: Robert L Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
-
Publication number: 20240018121Abstract: Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.Type: ApplicationFiled: June 3, 2021Publication date: January 18, 2024Applicant: FOX CHASE CHEMCIAL DIVERSITY CENTER, INC.Inventors: Simon David Peter BAUGH, Kathryn B. FREEMAN, Jeffrey Claude PELLETIER, Allen B. REITZ, Richard W. SCOTT, Garry Robert SMITH, Sandeep THANNA, Damian G. WEAVER, David B. WHITMAN
-
Publication number: 20210284651Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.Type: ApplicationFiled: May 25, 2021Publication date: September 16, 2021Inventors: Robert L. Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
-
Patent number: 11046707Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.Type: GrantFiled: December 14, 2017Date of Patent: June 29, 2021Assignee: 89BIO LTDInventors: Robert L. Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
-
Publication number: 20200031840Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.Type: ApplicationFiled: December 14, 2017Publication date: January 30, 2020Inventors: Robert L. HUDKINS, David B. WHITMAN, Craig A. ZIFICSAK, Allison L. ZULLI, Melody MCWHERTER
-
Patent number: 8685961Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: March 27, 2007Date of Patent: April 1, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Karen M. Brashear, Paul J. Coleman, Christopher D. Cox, Anthony M. Smith, David B. Whitman
-
Patent number: 8669272Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 15, 2009Date of Patent: March 11, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
-
Patent number: 8263586Abstract: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: May 14, 2008Date of Patent: September 11, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher D. Cox, David B. Whitman
-
Publication number: 20110319409Abstract: The present invention is directed to 7-aza-quinazoline compounds of general structural formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).Type: ApplicationFiled: June 23, 2010Publication date: December 29, 2011Inventors: Christopher D. Cox, Izzat T. Raheem, Broc A. Flores, David B. Whitman
-
Publication number: 20110251237Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: October 15, 2009Publication date: October 13, 2011Applicant: MERCK SHARP & DOHME CROP.Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
-
Publication number: 20100227848Abstract: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: May 14, 2008Publication date: September 9, 2010Inventors: Christopher D. Cox, David B. Whitman
-
Publication number: 20100029736Abstract: The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: July 13, 2007Publication date: February 4, 2010Applicant: MERCK & CO., INC.Inventors: Christopher D. Cox, David B. Whitman, Michael J. Breslin
-
Publication number: 20090258903Abstract: The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: July 31, 2006Publication date: October 15, 2009Inventors: Paul J. Coleman, Christopher D. Cox, David B. Whitman
-
Patent number: 7595337Abstract: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.Type: GrantFiled: February 6, 2006Date of Patent: September 29, 2009Assignee: Merck & Co. Inc.Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Lou Anne Neilson, David B. Whitman
-
Publication number: 20090176789Abstract: The present invention is directed to diazaspirodecane compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: August 24, 2006Publication date: July 9, 2009Inventors: Michael J. Breslin, Christopher D. Cox, David B. Whitman
-
Publication number: 20090124603Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: March 27, 2007Publication date: May 14, 2009Inventors: Karen M. Brashear, Paul J. Coleman, Christopher D. Cox, Anthony M. Smith, David B. Whitman
-
Publication number: 20090118200Abstract: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: May 22, 2006Publication date: May 7, 2009Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Craig Lindsley, Swati Pal Mercer, Anthony J. Roecker, David B. Whitman
-
Publication number: 20080182843Abstract: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.Type: ApplicationFiled: February 6, 2006Publication date: July 31, 2008Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Lou Anne Neilson, David B. Whitman
-
Patent number: 7402577Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.Type: GrantFiled: September 27, 2002Date of Patent: July 22, 2008Assignee: Merck & Co., Inc.Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman